Spherix Global Insights’ Latest Market Dynamix™ Report Reveals Intensifying Complexity in Relapsed/Refractory Multiple Myeloma Ahead of ASH 2025 Exton, PA.,
One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time
New chart-audit data reveal faster referrals, more patients initiating advanced therapy before hematology consultation, and heightened disease awareness among community physicians. Exton,
New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and
Physicians highlight early intervention, safety, and access limitations as key unmet needs—Tepezza SC anticipated to reshape the treatment paradigm in
Familiarity with AstraZeneca’s Saphnelo and enthusiasm for next-generation biologics signal increasing optimism, though CAR T-cell therapy divides opinion amid safety
Strong enthusiasm for novel modalities is tempered by neurologists’ demands for clinically meaningful endpoints and data superiority, according to Spherix
Exton, PA., October 31, 2025 — Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1
New analysis from Spherix Global Insights reveals 90% retention on first-line gMG biologics, with Alexion’s Ultomiris® and argenx’s Vyvgart® (IV)
Exton, PA., October 28, 2025 – The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling
Despite two recent FDA approvals, two-thirds of physicians report high unmet need in CSU, highlighting potential for clinical advancement, according
New Spherix Global Insights data reveal growing physician demand for therapies that reduce treatment burden and elevate patient experience. EXTON,
